ArticleNeuro-oncology2022

Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors.

Akifumi Hagiwara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.